Humanigen
Henry Madrid's work experience includes:
- Senior Consultant at Roseryan (no specific start or end dates provided)
- Vice President of Finance at Humanigen, Inc. starting in March 2021 (no specific end date provided)
- Manager at Pricewaterhouse from 1979 to 1986.
From 1975 to 1979, Henry Madrid attended Santa Clara University. However, no specific degree or field of study information is available for this period.
This person is not in any teams
Humanigen
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.